Key players operating in the autologous matrix-induced chondrogenesis market include Biotissue AG, Arthro-Kinetics, JRL Orthopaedic Ltd, B Braun, Melsungen AG, Matricel GmbH, Geistlich Pharma AG, and Zimmer Biomet Holdings.
The growing prevalence of joint and bone disorders such as osteoporosis and arthritis around the globe is expected to foster the growth of the autologous matrix-induced chondrogenesis market. According to recent statistics from the International Osteoporosis Foundation, worldwide, 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporotic fractures in their lifetime. Also, according to the World Health Organization, people aged 45 years and above in the U.S. and Europe show higher rates of osteoarthritis; 14.1% among men and 22.8% among women increasing demand for minimally invasive surgeries around the globe is again fostering the growth of the autologous matrix-induced chondrogenesis market. Autologous matrix-induced chondrogenesis is a type of one-step minimal invasive technique.
North America is expected to dominate the global market over the forecast period and this is attributed to the high number of surgeries performed in the region. For instance, according to the American Academy of Orthopaedic Surgeons (AAOS) 2019 report, around 267,000 knee replacements are performed each year in the U.S. This is also accounted for an increasing number of sports-related surgeries in the region. For instance, according to National Safety Council (NSC) report, in 2017, over 526,000 sports-related injuries were reported in the U.S.
Autologous Matrix-induced chondrolysis is an innovative treatment for traumatic articular cartilages (also called menisci). It combines the administration of facial collagen I/ III protein bi-product with microfracture surgery. This procedure involves creating a microscopic incision along with the articular cartilages under the skin so as to expose a fresh layer of connective tissue, which fills in space where nerves and articular discs were formerly located. The body's natural ability to produce this collagen protein itself has been found to be sufficient enough to stave off or even reverse atrophy of the skin, thus enabling the patient to resume their previously active lifestyle.
According to research, this procedure has been used to treat spinal injuries for decades, but only recently it has become available for athletes and those who suffered from serious and debilitating sporting injuries. The procedure involves several sessions that last for about ten years, with each session lasting for about four hours. Each session usually involves two to three hours of manual manipulation of the affected area, as well as a brief time of rest before returning for another session. Each session usually lasts about ten hours, but this can vary depending on the severity of the injury.